首页> 外文期刊>Nature clinical practice. Cardiovascular medicine >Are thiazolidinediones associated with an increased risk of heart failure and cardiovascular death?
【24h】

Are thiazolidinediones associated with an increased risk of heart failure and cardiovascular death?

机译:噻唑烷二酮与心力衰竭和心血管死亡的风险增加相关吗?

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The peroxisome-proliferator-activated receptor y (PPAR-gamma) agonists thiazolidinediones (e.g. pioglitazone and rosiglitazone) are used for glycemic control in patients with type 2 diabetes. Studies have indicated that these agents have a poor cardiovascular safety profile and are reportedly associated with increased fluid retention leading to heart failure (HF).
机译:过氧化物酶体-增殖物激活的受体y(PPAR-γ)激动剂噻唑烷二酮(例如吡格列酮和罗格列酮)用于2型糖尿病患者的血糖控制。研究表明,这些药物的心血管安全性较差,据报道与液体滞留增加有关,导致心力衰竭(HF)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号